Pharma Focus Asia

SK bioscience Expands its Vaccine Manufacturing Facility in Andong, South Korea

Introduction:

SK bioscience plans to expand its vaccine manufacturing facility in Andong, South Korea.

Features:

The expansion enhances manufacturing capabilities for global supply by extending the vaccine manufacturing department with the addition of two floors, resulting in approximately 4,200 square metres of additional space.

This expanded area will serve as the production base for the next-generation pneumococcal conjugate vaccine candidate, ‘GBP410’ (also referred to as SP0202).

In addition to expanding the facility, it also plans to swiftly obtain cGMP (Current Good Manufacturing Practise) certification for the new facility.

This facility will be constructed as a pilot plant, dedicated to conducting small-scale tests before the implementation of a new process or product, thereby ensuring quality and efficiency.

The facility expansion will serve as a pivotal global vaccine hub, positioning itself at the forefront of vaccine production and distribution.

Specifications:

Name    SK bioscience
Type      Expansion

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference